KR19990082463A
(ko)
|
1996-02-13 |
1999-11-25 |
돈 리사 로얄 |
혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DK0885198T3
(da)
|
1996-03-05 |
2002-03-25 |
Astrazeneca Ab |
4-Anilinoquinazolinderivater
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
CN1252054C
(zh)
|
1996-09-25 |
2006-04-19 |
曾尼卡有限公司 |
抑制生长因子的作用的喹啉衍生物
|
EP1005470B1
(en)
|
1997-08-22 |
2007-08-01 |
AstraZeneca AB |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
GB9800569D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
SI2253620T1
(sl)
|
1998-09-29 |
2014-06-30 |
Wyeth Holdings Llc |
Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz
|
ES2241324T3
(es)
*
|
1998-10-08 |
2005-10-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
KR20080015482A
(ko)
|
1999-02-10 |
2008-02-19 |
아스트라제네카 아베 |
혈관형성 억제제로서의 퀴나졸린 유도체
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
JP2003503354A
(ja)
|
1999-06-30 |
2003-01-28 |
メルク エンド カムパニー インコーポレーテッド |
Srcキナーゼ阻害剤化合物
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
CA2383546A1
(en)
|
1999-06-30 |
2001-01-04 |
William H. Parsons |
Src kinase inhibitor compounds
|
WO2001004111A1
(en)
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
JP4102185B2
(ja)
*
|
2000-06-30 |
2008-06-18 |
グラクソ グループ リミテッド |
キナゾリンジトシル酸塩化合物
|
NZ523358A
(en)
|
2000-08-09 |
2004-09-24 |
Astrazeneca Ab |
Quinoline derivatives having VEGF inhibiting activity
|
MXPA03001332A
(es)
|
2000-08-21 |
2004-07-08 |
Astrazeneca Ab |
Derivados de quinazolina.
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
DE60128709T2
(de)
*
|
2000-09-15 |
2007-12-27 |
Vertex Pharmaceuticals Inc., Cambridge |
Triazol-verbindungen als protein-kinase-inhibitoren
|
MXPA03002411A
(es)
*
|
2000-09-20 |
2003-06-19 |
Merck Patent Gmbh |
4-amino-quinazolinas.
|
EP1318984A1
(en)
*
|
2000-09-20 |
2003-06-18 |
MERCK PATENT GmbH |
4-amino-quinazolines
|
JP5260818B2
(ja)
*
|
2000-09-29 |
2013-08-14 |
ノバルティス・インターナショナル・ファーマシューティカル・リミテッド |
高親和性低分子C5a受容体調節物質
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6849625B2
(en)
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
EP1337513A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
4-substituted quinolines as antitumor agents
|
KR100947185B1
(ko)
|
2000-12-21 |
2010-03-15 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
|
EP1399483B1
(en)
|
2001-01-05 |
2010-04-14 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
JP4458746B2
(ja)
*
|
2001-01-16 |
2010-04-28 |
グラクソ グループ リミテッド |
癌の治療方法
|
PT1370553E
(pt)
*
|
2001-03-23 |
2006-09-29 |
Bayer Corp |
Inibidores de rhoquinase
|
ES2280517T3
(es)
*
|
2001-03-23 |
2007-09-16 |
Bayer Pharmaceuticals Corporation |
Inhibidor de rho-cinasa.
|
DE60229046D1
(de)
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
BR0213842A
(pt)
*
|
2001-11-03 |
2004-08-31 |
Astrazeneca Ab |
Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
JP4202926B2
(ja)
*
|
2001-12-12 |
2008-12-24 |
ファイザー・プロダクツ・インク |
E−2−メトキシ−n−(3−(4−(3−メチル−ピリジン−3−イロキシ)−フェニルアミノ)−キナゾリン−6−イル)−アリル)−アセトアミドの塩形態、その製造および癌に対するその使用
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
DE60320933D1
(de)
*
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
Rho-kinase inhibitoren
|
BR0306982A
(pt)
*
|
2002-01-17 |
2004-10-26 |
Neurogen Corp |
Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto
|
JP4423043B2
(ja)
|
2002-01-23 |
2010-03-03 |
バイエル ファーマセチカル コーポレーション |
Rho−キナーゼ阻害剤
|
WO2003062225A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
PL371486A1
(en)
|
2002-02-01 |
2005-06-13 |
Astrazeneca Ab |
Quinazoline compounds
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US20050176740A1
(en)
*
|
2002-04-08 |
2005-08-11 |
Spector Neil L. |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
AU2003281193A1
(en)
|
2002-07-09 |
2004-01-23 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP2280003B1
(en)
|
2002-07-15 |
2014-04-02 |
Symphony Evolution, Inc. |
Process for preparing receptor-type kinase modulators
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
CA2494100C
(en)
|
2002-08-02 |
2011-10-11 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of gsk-3
|
AU2003273675A1
(en)
*
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
RU2350618C2
(ru)
|
2002-11-04 |
2009-03-27 |
Астразенека Аб |
ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
EP1569925A1
(en)
*
|
2002-12-13 |
2005-09-07 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
NZ540340A
(en)
|
2002-12-19 |
2007-07-27 |
Pfizer |
2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
GEP20084357B
(en)
|
2002-12-20 |
2008-04-29 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
OA13151A
(en)
|
2003-02-26 |
2006-12-13 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors.
|
AU2004221812B2
(en)
*
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
US7618975B2
(en)
*
|
2003-07-03 |
2009-11-17 |
Myriad Pharmaceuticals, Inc. |
4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
US20060204966A1
(en)
*
|
2003-08-01 |
2006-09-14 |
Spector Neil L |
Treatment of cancers expressing p95 erbb2
|
DK1660090T3
(da)
|
2003-08-14 |
2012-12-17 |
Array Biopharma Inc |
Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
MXPA06002296A
(es)
|
2003-08-29 |
2006-05-22 |
Pfizer |
Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
AU2004270740A1
(en)
*
|
2003-09-09 |
2005-03-17 |
Neurogen Corporation |
4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CA2538884C
(en)
|
2003-09-16 |
2010-09-21 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
SI2213661T1
(sl)
*
|
2003-09-26 |
2011-11-30 |
Exelixis Inc |
c-Met modulatorji in postopki uporabe
|
EP1683785B1
(en)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
US7511065B2
(en)
*
|
2003-11-12 |
2009-03-31 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
DK1689721T3
(da)
*
|
2003-11-26 |
2010-09-20 |
Pfizer Prod Inc |
Aminopyrazolderivater som GSK-3-ihibitorer
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
UA85706C2
(en)
|
2004-05-06 |
2009-02-25 |
Уорнер-Ламберт Компани Ллси |
4-phenylaminoquinazolin-6-yl amides
|
US7452887B2
(en)
|
2004-06-04 |
2008-11-18 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
WO2006008639A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
WO2006021884A2
(en)
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
CN101056639A
(zh)
|
2004-09-15 |
2007-10-17 |
詹森药业有限公司 |
噻唑并吡啶激酶抑制剂
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
CN101124228B
(zh)
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
CA2599328C
(en)
|
2005-02-23 |
2012-04-17 |
Shionogi & Co., Ltd. |
Quinazoline derivative having tyrosine kinase inhibitory activity
|
EP3300739A3
(en)
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
US7579356B2
(en)
|
2005-05-04 |
2009-08-25 |
Janssen Pharmaceutica Nv |
Thia-tetraazaacenaphthylene kinase inhibitors
|
KR20080030058A
(ko)
|
2005-07-27 |
2008-04-03 |
에프. 호프만-라 로슈 아게 |
5-ht6 조절인자로서 4-아릴옥시 퀴놀린 유도체
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
MY164457A
(en)
|
2005-09-07 |
2017-12-15 |
Amgen Fremont Inc |
Human monoclonal antibodies to activin receptor-like kinase-1
|
US7732613B2
(en)
*
|
2005-09-14 |
2010-06-08 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
ATE533057T1
(de)
|
2005-09-20 |
2011-11-15 |
Osi Pharm Inc |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
GB0520475D0
(en)
*
|
2005-10-07 |
2005-11-16 |
Arrow Therapeutics Ltd |
Chemical compounds
|
NZ594385A
(en)
|
2005-11-03 |
2013-02-22 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
EP1971601B1
(en)
|
2005-11-15 |
2009-10-21 |
Array Biopharma Inc. |
N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
DE602007014324D1
(de)
*
|
2006-01-11 |
2011-06-16 |
Arrow Therapeutics Ltd |
Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel
|
DE102006012251A1
(de)
*
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
US20110053964A1
(en)
*
|
2006-08-22 |
2011-03-03 |
Roger Tung |
4-aminoquinazoline derivatives and methods of use thereof
|
CN101594870A
(zh)
*
|
2006-08-22 |
2009-12-02 |
康塞特医药品有限公司 |
4-氨基喹唑啉衍生物及其使用方法
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
KR101129868B1
(ko)
*
|
2006-10-04 |
2012-04-12 |
화이자 프로덕츠 인코포레이티드 |
칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
|
KR101546493B1
(ko)
|
2006-11-06 |
2015-08-21 |
톨레로 파마수티컬스, 인크. |
이미다조[1,2-b]피리다진 및 피라졸로[1,5-a]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
EP2121681B1
(en)
|
2007-01-11 |
2015-04-15 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
MX2009007610A
(es)
|
2007-02-06 |
2009-07-24 |
Boehringer Ingelheim Int |
Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
|
WO2008124083A2
(en)
|
2007-04-05 |
2008-10-16 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
WO2008127710A2
(en)
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute |
Methods for treating cancer resistant to erbb therapeutics
|
CN101678215B
(zh)
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
MX2009011810A
(es)
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
WO2009012647A1
(fr)
*
|
2007-07-20 |
2009-01-29 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Procédés de préparation de dérivés de quinazoline et leurs utilisations pharmaceutiques
|
CN101367794B
(zh)
*
|
2007-07-20 |
2013-07-10 |
上海恒瑞医药有限公司 |
喹唑啉类衍生物的制备方法及其在医药上的应用
|
WO2009018415A1
(en)
|
2007-07-31 |
2009-02-05 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
WO2009026303A1
(en)
|
2007-08-21 |
2009-02-26 |
Amgen Inc. |
Human c-fms antigen binding proteins
|
WO2009033094A2
(en)
|
2007-09-07 |
2009-03-12 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24p4c12 proteins
|
WO2009052379A2
(en)
*
|
2007-10-19 |
2009-04-23 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
MY150054A
(en)
|
2007-10-29 |
2013-11-29 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
AU2009209541A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
EP2245026B1
(de)
|
2008-02-07 |
2012-08-01 |
Boehringer Ingelheim International GmbH |
Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
MX2010009782A
(es)
*
|
2008-03-07 |
2010-09-30 |
Pharma Mar Sa |
Tratamientos antitumorales mejorados.
|
WO2009117157A1
(en)
|
2008-03-20 |
2009-09-24 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
WO2009126662A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
US8252805B2
(en)
*
|
2008-05-07 |
2012-08-28 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib ditosylate and processes for preparation thereof
|
MX2010012442A
(es)
|
2008-05-13 |
2011-10-11 |
Astrazeneca Ab |
Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
WO2010017387A2
(en)
*
|
2008-08-06 |
2010-02-11 |
Teva Pharmaceutical Industries Ltd. |
Lapatinib intermediates
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
WO2010019473A1
(en)
|
2008-08-14 |
2010-02-18 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
WO2010027848A2
(en)
*
|
2008-08-26 |
2010-03-11 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib compounds and processes for the preparation thereof
|
AU2009289316A1
(en)
*
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Bicyclic kinase inhibitors
|
EP2323622A1
(en)
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
EP2387563B2
(en)
|
2009-01-16 |
2022-04-27 |
Exelixis, Inc. |
Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
CN101787017A
(zh)
*
|
2009-01-23 |
2010-07-28 |
岑均达 |
光学纯喹唑啉类化合物
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
EP2270002A1
(en)
|
2009-06-18 |
2011-01-05 |
Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg |
Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
|
SG10201403696UA
(en)
|
2009-06-29 |
2014-10-30 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
EP2448409A4
(en)
|
2009-07-02 |
2013-04-10 |
Newgen Therapeutics Inc |
PHOSPHOROUS CHINAZOLIN COMPOUNDS AND METHOD OF USE THEREOF
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CN102770140B
(zh)
|
2009-08-21 |
2017-06-23 |
诺瓦蒂斯公司 |
治疗癌症的方法
|
EP2473500A2
(en)
|
2009-09-01 |
2012-07-11 |
Pfizer Inc. |
Benzimidazole derivatives
|
CN102753535B
(zh)
|
2009-09-03 |
2015-03-25 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的喹唑啉
|
US8916574B2
(en)
|
2009-09-28 |
2014-12-23 |
Qilu Pharmaceutical Co., Ltd. |
4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
|
AR078986A1
(es)
|
2009-11-12 |
2011-12-14 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas
|
EP2510110A1
(en)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US20110207736A1
(en)
|
2009-12-23 |
2011-08-25 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
CN102108079B
(zh)
*
|
2009-12-25 |
2014-10-01 |
齐鲁制药有限公司 |
作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
|
CA2781578A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
CN102153544B
(zh)
*
|
2010-02-12 |
2015-04-29 |
上海阳帆医药科技有限公司 |
一类酪氨酸激酶抑制剂的制备及用途
|
DK3150610T3
(da)
|
2010-02-12 |
2019-11-04 |
Pfizer |
Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
JP2013527748A
(ja)
|
2010-03-03 |
2013-07-04 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
KR20130001272A
(ko)
|
2010-03-17 |
2013-01-03 |
에프. 호프만-라 로슈 아게 |
이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법
|
EP2550269B1
(en)
*
|
2010-03-23 |
2016-03-23 |
Scinopharm Taiwan Ltd. |
Process and intermediates for preparing lapatinib
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
WO2011130654A1
(en)
|
2010-04-16 |
2011-10-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
EP3135692B8
(en)
|
2010-06-16 |
2019-03-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
EP2586443B1
(en)
|
2010-06-25 |
2016-03-16 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
MX2013002084A
(es)
|
2010-08-31 |
2013-05-09 |
Genentech Inc |
Biomarcadores y metodos de tratamiento.
|
AR082974A1
(es)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
|
CA2813162C
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2- derivatives as smoothened receptor modulators
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
CN102552271B
(zh)
*
|
2010-12-09 |
2014-08-06 |
中国科学院上海药物研究所 |
一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
WO2012122058A2
(en)
|
2011-03-04 |
2012-09-13 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
BR112013022307A2
(pt)
|
2011-03-04 |
2020-09-24 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
aminoquinolinas como inibidores de quinase
|
ES2740399T3
(es)
|
2011-03-09 |
2020-02-05 |
Richard G Pestell |
Líneas de células de cáncer de próstata, firmas genéticas y usos de estas
|
WO2012125913A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
WO2012125904A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of egfr
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
AU2012246490B2
(en)
|
2011-04-18 |
2016-08-04 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
CA3019531A1
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013013188A1
(en)
|
2011-07-21 |
2013-01-24 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
RU2014105624A
(ru)
|
2011-08-12 |
2015-09-20 |
Ф. Хоффманн-Ля Рош Аг |
Соединения индазола, способ их применения и фармацевтическая композиция
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
JP6297490B2
(ja)
|
2011-08-31 |
2018-03-20 |
ジェネンテック, インコーポレイテッド |
診断マーカー
|
CN103827115A
(zh)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶化合物、组合物和使用方法
|
MD20140023A2
(ro)
|
2011-09-22 |
2014-06-30 |
Pfizer Inc. |
Derivaţi de pirolpirimidină şi purină
|
AU2012321248A1
(en)
|
2011-09-30 |
2014-04-24 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
WO2013060881A1
(en)
|
2011-10-27 |
2013-05-02 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Pyridopyrimidines and their therapeutic use
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
CN106987620A
(zh)
|
2011-11-30 |
2017-07-28 |
霍夫曼-拉罗奇有限公司 |
癌症中的erbb3突变
|
CN103172641B
(zh)
|
2011-12-20 |
2014-06-11 |
钱卫 |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
KR20140117644A
(ko)
|
2012-01-31 |
2014-10-07 |
스미스클라인 비이참 (코르크) 리미티드 |
암을 치료하는 방법
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
EP2834246B1
(en)
|
2012-04-03 |
2021-07-28 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CA2873743C
(en)
|
2012-05-14 |
2022-12-06 |
Prostagene, Llc |
Using modulators of ccr5 for treating cancer
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基-喹啉類
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
US9334239B2
(en)
|
2012-12-21 |
2016-05-10 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
ES2654100T3
(es)
|
2013-02-21 |
2018-02-12 |
Glaxosmithkline Intellectual Property Development Limited |
Quinazolinas como inhibidores de quinasa
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
WO2014139326A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
CN105308033B
(zh)
|
2013-03-14 |
2018-08-24 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
BR112015023203A8
(pt)
|
2013-03-15 |
2018-01-23 |
Constellation Pharmaceuticals Inc |
métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
|
US20160051556A1
(en)
|
2013-03-21 |
2016-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
AU2014266223B2
(en)
|
2013-05-14 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US9505767B2
(en)
|
2013-09-05 |
2016-11-29 |
Genentech, Inc. |
Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
JP6946000B2
(ja)
|
2013-10-04 |
2021-10-06 |
アプトース バイオサイエンシーズ, インコーポレイテッド |
がんの治療用組成物及び方法
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
CN103554091B
(zh)
*
|
2013-11-05 |
2016-05-18 |
沈阳工业大学 |
喹唑啉衍生物及其制备方法和用途
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CA2931589C
(en)
*
|
2013-12-09 |
2022-01-04 |
Ucb Biopharma Sprl |
Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
|
BR112016013896A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
|
CN106102774A
(zh)
|
2013-12-17 |
2016-11-09 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
HUE046767T2
(hu)
|
2014-03-31 |
2020-03-30 |
Hoffmann La Roche |
Anti-OX40 antitestek és alkalmazási eljárások
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
NZ725496A
(en)
|
2014-04-30 |
2019-11-29 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとegfr阻害剤の組合せ
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
AU2015362670B2
(en)
|
2014-12-15 |
2019-01-24 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of EGFR and PI3K
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
EP3237639A2
(en)
|
2014-12-23 |
2017-11-01 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
RU2739942C2
(ru)
|
2014-12-24 |
2020-12-30 |
Дженентек, Инк. |
Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
CN107406429B
(zh)
|
2015-01-09 |
2021-07-06 |
基因泰克公司 |
哒嗪酮衍生物及其在治疗癌症中的用途
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
MX2017013383A
(es)
|
2015-04-20 |
2017-12-07 |
Tolero Pharmaceuticals Inc |
Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
|
MX2017013956A
(es)
|
2015-05-01 |
2018-09-05 |
Cocrystal Pharma Inc |
Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
|
LT3294770T
(lt)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo ir diagnostikos būdai
|
EP3298021B1
(en)
|
2015-05-18 |
2019-05-01 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
MX2017014736A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
US20160355597A1
(en)
|
2015-06-08 |
2016-12-08 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
EP3317323B1
(en)
|
2015-07-01 |
2021-05-26 |
California Institute of Technology |
Cationic mucic acid polymer-based delivery systems
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
AU2016301315C1
(en)
|
2015-08-03 |
2022-07-07 |
Sumitomo Pharma Oncology, Inc. |
Combination therapies for treatment of cancer
|
CN108026110B
(zh)
|
2015-08-26 |
2022-02-08 |
国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.Cnio) |
作为蛋白激酶抑制剂的稠合三环化合物
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
JP6740354B2
(ja)
|
2015-10-05 |
2020-08-12 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
|
AU2016364855B2
(en)
|
2015-12-03 |
2019-08-29 |
Les Laboratoires Servier |
MAT2A inhibitors for treating MTAP null cancer
|
EP3978500B1
(en)
|
2015-12-16 |
2023-11-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
CN107141293B
(zh)
|
2016-03-01 |
2022-09-23 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
JP6976265B2
(ja)
|
2016-03-08 |
2021-12-08 |
ヤンセン バイオテツク,インコーポレーテツド |
Gitr抗体、方法、及び使用
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
JP2019527037A
(ja)
|
2016-06-08 |
2019-09-26 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
JOP20190154B1
(ar)
|
2016-12-22 |
2022-09-15 |
Amgen Inc |
بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
US11578074B2
(en)
|
2017-09-01 |
2023-02-14 |
Shanghai Pharmaceuticals Holding Cd., Ltd. |
Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
|
TWI827550B
(zh)
|
2017-09-08 |
2024-01-01 |
美商建南德克公司 |
癌症之診斷及治療方法
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
EP3727387A4
(en)
|
2017-12-18 |
2021-12-15 |
Sterngreene, Inc. |
PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3802537A1
(en)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
KR20210062634A
(ko)
|
2018-09-21 |
2021-05-31 |
제넨테크, 인크. |
3중-음성 유방암에 대한 진단 방법
|
BR112021006407A8
(pt)
|
2018-10-04 |
2022-12-06 |
Inst Nat Sante Rech Med |
uso de inibidores do egfr para ceratodermas
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019391097A1
(en)
|
2018-12-04 |
2021-05-20 |
Sumitomo Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
US20220081438A1
(en)
|
2018-12-19 |
2022-03-17 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
CN113677994A
(zh)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
用于评估t细胞功能和预测对疗法的应答的方法和药剂
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
TW202108616A
(zh)
|
2019-05-03 |
2021-03-01 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114302880A
(zh)
|
2019-08-02 |
2022-04-08 |
美国安进公司 |
Kif18a抑制剂
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
CR20220095A
(es)
|
2019-09-04 |
2022-06-06 |
Genentech Inc |
Agentes de unión a cd8 y usos de los mismos
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
BR112022008565A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
CN112778217B
(zh)
*
|
2019-11-08 |
2024-01-26 |
沈阳化工研究院有限公司 |
一种喹唑啉类化合物及其应用
|
CN114728905A
(zh)
|
2019-11-13 |
2022-07-08 |
基因泰克公司 |
治疗性化合物及使用方法
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
MX2022005708A
(es)
|
2019-11-14 |
2022-06-08 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック, インコーポレイテッド |
抗tigitアンタゴニスト抗体を用いたがんを処置するための方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
EP4214209A1
(en)
|
2020-09-15 |
2023-07-26 |
Revolution Medicines, Inc. |
Indole derivatives as ras inhibitors in the treatment of cancer
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4225443A1
(en)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
AR124449A1
(es)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
Inhibidores de sos1 y usos de los mismos
|
CA3206168A1
(en)
|
2020-12-22 |
2022-06-30 |
Mekanistic Therapeutics Llc |
Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|